

US magazine Wired covers migraine and Chordate's Ozilia treatment

The American magazine Wired recently published an article on neuromodulation as an emerging method for treating migraines. Wired describes the technique as a “non-invasive method that can reprogram nerve signals” and potentially provide an effective alternative for patients who do not respond to traditional medications.

[The Wired article](#) highlights Chordate Medical's development of the Ozilia treatment, which targets a specific nerve cluster in the nose (sphenopalatine ganglion) to alleviate migraine symptoms. It also emphasizes how neuromodulation, being drug-free and with minimal side effects, could challenge conventional approaches.

Several researchers are quoted, explaining that by stimulating the nervous system through the nose, this method may influence the onset and intensity of migraines, offering hope to patients searching for new options.

“Beyond awareness in the healthcare sector and research community, this type of international media attention is, of course, positive. The more people become aware of neuromodulation as an effective and safe migraine treatment, the greater the opportunity to establish Ozilia as a recognized treatment available to people suffering from migraines worldwide,” says Anders Weilandt, CEO of Chordate.

Chordate Medical has an ongoing project to obtain FDA market approval for the Ozilia treatment method and was granted a [fourth patent](#) in the United States as recently as May this year.

[Read the full article in WIRED](#)

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

Press Release
02 October 2024 08:30:00 CEST

CHORDATE
M E D I C A L

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[US magazine Wired covers migraine and Chordate's Ozilia treatment](#)